EORTC risk tables - their usefulness in the assessment of recurrence and progression risk in non-muscle-invasive bladder cancer in Polish patients

被引：13

作者：

Borkowska, Edyta M. ^{[1
,3
]}

Jedrzejczyk, Adam ^{[1
,2
]}

Marks, Piotr ^{[2
]}

Catto, James W. F. ^{[3
]}

Kaluzewski, Bogdan ^{[1
]}

机构：

[1] Med Univ Lodz, Dept Clin & Lab Genet, 3 Sterlinga St, PL-91425 Lodz, Poland

[2] John Paul II Mem Reg Hosp Belchatow, Div Urol, Belchatow, Poland

[3] Univ Sheffield, Inst Canc Studies & Acad Urol Unit, Sheffield, S Yorkshire, England

来源：

CENTRAL EUROPEAN JOURNAL OF UROLOGY | 2013年 / 66卷 / 01期

关键词：

bladder cancer; EORTC risk tables; recurrence; progression;

D O I：

10.5173/ceju.2013.01.art5

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction. The assessment of risk of recurrence and progression of bladder cancer (BC) is still rather difficult. We decided to check the rates of the changes mentioned above in the group of the Polish patients after a year-long observation and next to compare them with the results calculated in the European Organisation of Research and Treatment of Cancer (EORTC) risk tables. Methods. The tested group consisted of 91 patients who underwent transurethral resection of bladder tumour (TURBT). When being diagnosed, 60 cases were in the pTa clinical stage, whereas 30 cases were in T1. The coexisting carcinoma in situ (CIS) was observed in four cases. On the basis of the scores obtained from the EORTC tables, the patients were divided into the groups of low, intermediate or high risk of disease recurrence and progression. Results. Recurrence was noticed in 23 patients (25%), while progression was observed in 11 patients (12.1%). The rate of the observed recurrences proved to be lower than it had been predicted in all the groups, except for one of the intermediate-risk group (score 1-4). Moreover, the rate of the progressions predicted according to the EORTC risk tables was higher in all the risk groups. Conclusions. It can be noticed that the rate of real recurrences is lower than expected, whereas the rate of the observed progressions is overestimated. Partly, it could be the result of using a relatively small group of patients for observation and applying a different method of treatment.

引用

页码：14 / 20

页数：7

共 34 条

[1]

Burger M., Catto J.W.F., Dalbagni G., Grossman H.B., Herr H., Karakiewicz P., Et al., Epidemiology and risk factors of urothelial bladder cancer, Eur Urol, 63, pp. 234-241, (2013)

[2]

Didkowska J., Wojciechowska U., Zatonski W., Cancer in Poland in Polish National Cancer Registry, Department of Epidemiology and Cancer Prevention, 2011, (2009)

[3]

Kirkali Z., Chan T., Manoharan M., Algaba F., Busch C., Cheng L., Et al., Bladder cancer: Epidemiology, staging and grading, and diagnosis, Urology, 66, pp. 4-34, (2005)

[4]

Thomas F., Rosario D.J., Rubin N., Goepel J.R., Abbod M.F., Catto J.W., The long term outcome of treated high-risk nonmuscle invasive bladder cancer, Cancer, 118, pp. 5525-5534, (2012)

[5]

Brennan P., Bogillot O., Cordier S., Greiser E., Schill W., Vineis O., Et al., Cigarette smoking and bladder cancer in men: A pooled analysis of 11 casecontrol studies, Int J Cancer, 86, pp. 289-294, (2000)

[6]

van Rhijn B., Burger M., Lotan Y., Solsona E., Stief C.G., Sylvester R.J., Et al., Recurrence and progression of disease in non-muscle- invasive bladder cancer: From epidemiology to treatment, Eur Urol, 56, pp. 430-442, (2009)

[7]

Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., Et al., Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials, Eur Urol, 49, pp. 466-477, (2006)

[8]

Mostofi K., Sobin L.H., Histologic typing of urinary bladder tumors, International Histological Classification of Tumors, (1973)

[9]

Hajdinjak T., UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing, Urol Oncol, 26, pp. 646-651, (2008)

[10]

Kipp B.R., Tanasescu M., Else T.A., Bryant S.C., Karnes R.J., Sebo T.J., Et al., Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer, J Mol Diagn, 11, pp. 148-154, (2009)

← 1 2 3 4 →